Melanoma - Global Drug Forecast and Market Analysis to 2023 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Melanoma - Global Drug Forecast and Market Analysis to 2023

Description:

Big Market Research present “PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis” Size, Share, Industry Trends, Demand, Analysis, Research, Report, Company Profiles, Forecast to 2023. Visit for more info @ Melanoma is the deadliest and most aggressive form of skin cancer. The major treatments for melanoma are categorized into immunotherapies and BRAF mutation-targeted therapies. GlobalData estimates the 2013 sales for melanoma at approximately $1.34 billion across the 8MM covered in this report. The market will increase by four-fold over the forecast period, reaching $5.64 billion in 2023 at a CAGR of 15.5%. – PowerPoint PPT presentation

Number of Views:26

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Melanoma - Global Drug Forecast and Market Analysis to 2023


1
PharmaPoint Melanoma
Global Drug Forecast and Market Analysis
to 2023
2
Report Description
Summary   Melanoma is the deadliest and most
aggressive form of skin cancer. The major
treatments for melanoma are categorized into
immunotherapies and BRAF mutation-targeted
therapies. GlobalData estimates the 2013 sales
for melanoma at approximately 1.34 billion
across the 8MM covered in this report. The market
will increase by four-fold over the forecast
period, reaching 5.64 billion in 2023 at a CAGR
of 15.5. This growth will be driven by an
increase in melanoma incident cases as well as
the approval and uptake of premium-priced
products, such as PD-1-targeting mAbs and
BRAF/MEK inhibitor combinations. GlobalData
expects, by the end of the forecast period, the
checkpoint immunotherapy drug class to dominate
the melanoma market (including both BRAF
wild-type and mutation-positive patient segments)
with an overall 67 share of the melanoma
market. The melanoma pipeline is strong
however, GlobalData expects none of these drugs
to have a major impact on the overall melanoma
market, as the market is crowded with effective
immunotherapies and BRAF mutation-targeted
agents. Read more details at
http//www.bigmarketresearch.com/pharmapoint-melan
oma-global-drug-forecast-and-analysis-to-2023-mark
et
3
Report Description
  • Key Questions Answered
  •  
  • The melanoma space is filled with the excitement
    of recently approved anti-PD-1 immunotherapies,
    which are expected to revolutionize the treatment
    landscape. What will be the impact of these newly
    approved drugs and their projected label
    expansions on the melanoma sales?
  • As the melanoma market is getting increasingly
    crowded with multiple anti-PD-1 immunotherapies
    and BRAF mutation-targeted agents, opportunities
    for new entrants become limited. What RD
    strategies are being used by drug makers to
    remain competitive?
  • The survival of patients with metastatic melanoma
    remains short, especially for those
  • who do not response to anti-PD-1
    immunotherapies. Therefore, there are
    considerably high unmet needs
    within the indication. What are the main unmet
    needs in this market. Will the drugs under
    development fulfil the unmet needs of the
    melanoma market?
  •  

4
Key Findings
  • Key Findings
  •  
  • One of the main drivers of the enormous expansion
    of the gout market will be the launch of
    premium-priced metastatic therapies, such as
    anti-PD-1 immunotherapy and BRAF/MEK inhibitor
    combinations. These drugs will extend treatment
    duration and replace cheaper, generic,
    chemotherapy regimens.
  • Another strong driver will be the label extension
    of current therapies into the new settings for
    example, PD-1s will garner label extension for
    the first-line treatment in 2015-16, and the
    metastatic brands are expected to be approved in
    the adjuvant setting in the second half of the
    forecast period.
  • Companies are focusing on the development of
    combination immunotherapies, trying to improve
    the response rate and response duration of drugs.
  • One of the largest unmet needs is a need for
    efficacious treatment options for BRAF wild-type
    patients. Approximately half of melanoma patients
    do not have BRAF mutations, and are therefore
    non-eligible for BRAF/MEK inhibitor treatments.
    Other unmet needs include therapies for PD-1
    immunotherapy non-responders, adjuvant treatment
    for patients with resected melanoma, effective
    treatment for brain metastasis

5
Scope
  • Scope
  •  
  • Overview of melanoma, including epidemiology,
    etiology, pathophysiology, symptoms, diagnosis,
    and disease management.
  • Annualized melanoma therapeutics market revenue,
    cost of therapy per patient, and treatment usage
    patterns in six patient segments (including
    adjuvant, BRAF mutated and BRAF wild-type),
    forecast from 2013 to 2023.
  • Key topics covered include strategic competitor
    assessment, market characterization, unmet needs,
    clinical trial mapping and implications for the
    melanoma therapeutics market
  • Pipeline analysis comprehensive data assessing
    emerging trends and mechanisms of action under
    development for different lines of therapy. The
    most promising candidate in Phase III development
    is profiled.

6
Reasons to buy
  • Reasons to buy
  •  
  • Develop and design your in-licensing and
    out-licensing strategies through a review of
    pipeline products and technologies, and by
    identifying the companies with the most robust
    pipeline.
  • Develop business strategies by understanding the
    trends shaping and driving the global melanoma
    therapeutics market.
  • Drive revenues by understanding the key trends,
    innovative products and technologies, market
    segments, and companies likely to impact the
    global melanoma therapeutics market in the
    future.
  • Formulate effective sales and marketing
    strategies by understanding the competitive
    landscape and by analysing the performance of
    various competitors.
  • About Report http//www.bigmarketresearch.com/rep
    ort-enquiry/308033

7
FOR MORE DETAILS
Visit us at
http//www.bigmarketresearch.com/pharmapoint-melan
oma-global-drug-forecast-and-analysis-to-2023-mark
et
Stay With Us
TELEPHONE 1-800-910-6452 EMAIL
help_at_bigmarketresearch.com
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
About PowerShow.com